October 07, 2026 11:02 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50% | ‘Completely false’: Virat Kohli reacts to ₹5 crore claim over Premanand Maharaj visit | We’re watching it very closely: US urges Russia to share more information on plague situation | This isn’t about schools: Trump blames ‘mass migration’ and Islam for violent protests across France | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘Vote thief’ Gyanesh Kumar: Rahul Gandhi climbs barricade, waves Tricolour during explosive INDIA bloc protest | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘He should not have been flying’: JD Vance on Flydubai co-pilot | Israel was ready to shoot down Flydubai jet if it kept flying towards Tel Aviv: Reports | 'If law wasn't followed, we can undo it': Supreme Court's big warning on SIR process amid Gyanesh Kumar row
India | COVID vaccines
Image Credit: Unsplash

In a big boost, Covaxin, Covishield get full market authorisation

| @indiablooms | Jan 20, 2022, at 06:12 am

New Delhi/IBNS: In a big boost to India's fight against COVID-19, an expert panel of the central drug authority on Wednesday cleared the country's two indigenous vaccines-Covaxin and Covishield-for full use.

The development comes a year after these vaccines' administration on an emergency-use basis started in India.

With this move, the vaccines are expected to be widely available at hospitals and clinics soon, which are registered with the government portal CoWIN.

This will also aid in booster doses, which Prime Minister Narendra Modi announced last month to be administered on health and frontline workers and adults above 60 years of age, as precautionary third doses.

The recommendation by the expert panel of the Central Drugs Standard Control Organisation (CDSCO) has been sent to the top drug regulator DGCI.

"SEC of CDSCO has recommended for the upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision," the regulatory body tweeted.

India’s COVID-19 vaccination coverage has crossed 159.54 Crore on Wednesday, the Union Health Ministery stated.

More than 62 lakh vaccine doses have been administered till 7 pm. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.